The first domestic oral small-molecule GLP-1 to read out a local Chinese Phase 3: how far has VCT220 sold itself?

First, lay out what this asset is made of.

Vincentage Pharma was founded in 2021 in Wuhou District, Chengdu, focusing on oral small molecules for metabolic diseases, with publicly disclosed cumulative financing of about US$20.3 million from shareholders including IDG Capital, Shenzhen Capital Group, Galaxy Industry and Everest Venture. As of May 2026, VCT220 is the company’s only asset in Phase 3; its two other early pipelines are discovery-stage GPR40 programs. The CEO is Ben Li (English name as disclosed); names of other executives such as CMO/CSO have not been disclosed in public channels.

VCT220 is also called CX11 — the latter name comes from Corxel Pharmaceuticals. On December 23, 2024, Vincentage reached a licensing deal with Corxel, transferring VCT220’s global rights outside Greater China to Corxel as a whole, with the territory covering everywhere outside mainland China, Hong Kong, Macau and Taiwan. Corxel continued development under the internal code CX11. Financial terms such as upfront, milestones and royalties have not been disclosed.

More than half a year later, on January 22, 2026, Corxel announced a US$287 million Series D1, from twelve investors including SR One, TCGX, RA Capital, RTW Investments and Hengdian Group, with Sandy Mou as CEO. This money is largely intended to fund ex-China global development of VCT220/CX11.

So today this molecule has three parallel clinical tracks:

• China obesity Phase 3 (NCT06939296, study VCT220-III-01), led by Vincentage, 840 patients, completed at 52 weeks, topline read out on May 18, 2026, with an NMPA NDA submission imminent.
• US/Poland type 2 diabetes Phase 2 (NCT07340320) and US obesity Phase 2, led by Corxel, with FDA IND cleared; topline readout described by the company as “later this year” (i.e. H2 2026).
• China essential hypertension Phase 2 + obesity with hypertension Phase 2 (NCT07360275), led by Vincentage, as second and third indication expansions of the same molecule.

The mechanism is a non-peptide small molecule that directly activates the GLP-1 receptor, taken orally once a day. Vincentage’s product positioning copy has two short, hard differentiation claims: no fasting required and no refrigeration or light protection required — the former targeting the real-world restriction of Lilly’s orforglipron currently of “take in the morning on an empty stomach, with no food for at least 30 minutes afterwards”, the latter targeting the storage and transport pain points of oral semaglutide.

China’s overweight and obese populations are widely put at around 600 million and 200 million, so there is no question mark on the demand side. The question mark is on the supply side: the window.

In the Chinese market, subcutaneous semaglutide, tirzepatide, liraglutide, dulaglutide and beinaglutide have already made GLP-1s an endocrinology consensus. The oral small-molecule lane has an unavoidable front-runner: Lilly’s orforglipron filed a marketing application with the NMPA at the end of 2025 and, per public reports, could be approved within 2026, very likely becoming the first oral small-molecule GLP-1 marketed in China (imported); combined with Lilly’s announced roughly US$3 billion expansion in China (including oral solid dosage capacity in Beijing), pressure from the imported originator is a landscape VCT220 must face squarely. In the domestic camp, as of May 2026 no oral small-molecule GLP-1 has launched: Hengrui’s HRS-7535 and Huadong Medicine’s HDM1002 are running Phase 3 in parallel, with start dates not far from VCT220’s; Ascletis’s ASC30 is in Phase IIa; Innovent’s IBI3032, Hansoh’s HS-10535 (licensed to Merck), Salubris’s SAL0112 and Sinopep’s SPN0103 are all in Phase 1.

In this landscape, VCT220’s odds come from three things: first in the domestic camp to read out a positive Phase 3 topline, among the first to file an NDA, and first to complete an ex-China rights deal. All three have already happened. But two points need a clear head: first, imported orforglipron will very likely be approved in China before all domestic products, so VCT220 was never competing for “China’s first oral small-molecule GLP-1” but for “the first domestic one”; second, if review is delayed by more than a year after NDA acceptance and either Hengrui’s HRS-7535 or Huadong’s HDM1002 is approved first, VCT220 would lose even “the first domestic one” — and the premium of the first-launch narrative would vanish immediately.

The more practical question is payers. Obesity is currently not on China’s NRDL; it is a typical self-pay + commercial insurance DTP model. Self-pay semaglutide currently costs RMB 1,800–3,000 a month; if domestic small molecules can come down to RMB 800–1,500, affordability would rise markedly, but margins would be squeezed. That is why the natural manufacturing cost advantage of oral small molecules over subcutaneous peptides becomes the core of the commercial story: API synthesis, solid dosage processes and cold-chain exemption together make COGS very likely an order of magnitude lower than any peptide route.

Laying out all the key nodes on VCT220’s road to NDA, the picture looks like this.

Parts already showing green:

• Safety performance: 52 weeks of treatment in 840 Phase 3 patients, with a discontinuation rate due to adverse events of only 1.8%, GI adverse events mainly mild to moderate, no severe nausea or vomiting and no liver toxicity signal. These are launch-grade safety data, and against Pfizer’s danuglipron, discontinued in 2025 for liver toxicity, they are a strong differentiator for VCT220.
• Phase 3 design: a three-arm monotherapy vs placebo design, randomized, with 52 weeks of treatment; the primary endpoint registered on ClinicalTrials.gov is percent change in body weight from baseline at week 34 (the company PR also reported extended 52-week data). The overall design is comparable to global obesity Phase 3 templates such as STEP, SURMOUNT and ATTAIN, and the choice of control arm is consistent with Chinese and global ethical consensus.
• US IND cleared by FDA, with Corxel leading the US obesity Phase 2 and US/Poland T2D Phase 2. This means the overseas registration path has substantively opened, and any future ex-China P3 design can continue directly from this data set.

Parts needing vigilance:

• IP details: Patsnap data show about 100 patents associated with VCT220, but the core compound patent number, PCT priority date, protection periods in major markets and the hierarchy of compound vs polymorph vs use patents have not been clearly disclosed in public channels. For an asset that realizes its value mainly through out-licensing, this is the due diligence package most in need of filling. In negotiations with the next ex-China regional partner (e.g. single regions such as Japan, Europe or Southeast Asia), IP transparency will convert directly into valuation.
• Expedited review channels: obesity in China does not qualify for urgent-clinical-need channels, and there is currently no public information showing VCT220 has entered Breakthrough Therapy, priority review, conditional approval or the Hainan Boao Lecheng channel. On the standard NDA path, review is expected to conclude between H2 2027 and 2028.
• A dense window of competitor readouts: over the next 12–18 months, key milestones for at least 5 direct competitors will cluster — the outcome of Lilly’s orforglipron China NDA review (filed, possibly approved within 2026) and its US progress, the Phase 3 of Hengrui’s HRS-7535, the Phase 3 of Huadong’s HDM1002, and the expansion cohorts of Ascletis’s ASC30. Orforglipron’s approval in China is the most certain and earliest of these: once it launches first, VCT220 will have to retell its value in the Chinese market from the angle of “benchmarking against an imported originator”. A head-to-head advantage or first approval by any of them would immediately re-price VCT220’s BD valuation and its expected Chinese market share.
• Blank spots in NMPA communication milestones: minutes of CDE communications such as pre-IND, pre-pivotal and pre-NDA meetings have not been made public. Being able to run Phase 3 implies substantive communication has occurred, but outside observers cannot judge whether the NMPA has given clear guidance on NDA acceptance criteria, control design or endpoint selection.
• Building payer evidence: weight endpoints are the hard metric payers care about, but China’s basic medical insurance does not cover the obesity indication and commercial insurance penetration is low, so the path to monetizing evidence-building is long. If long-term benefit data on cardiovascular and diabetes prevention can be added, acceptance by commercial insurance and corporate group insurance could rise significantly.

Looking only at Vincentage’s own balance sheet — US$20.3 million in cumulative financing, a single Phase 3 pipeline, and an obesity indication with dozens of GLP-1s already marketed globally in a red ocean — on paper this doesn’t look like a story that can independently complete China and US NDAs plus build its own commercial team. But Vincentage doesn’t intend to do that either.

The December 2024 ex-China license-out was a clear structural choice: retain independent development rights in Greater China + hand global clinical, regulatory, commercialization and CMC scale-up entirely to Corxel, a NewCo jointly backed by top biopharma VCs. In terms of timing, this BD happened around completion of the China Phase 2, just as Phase 3 started, and around US IND clearance — a timing of “after PoC, early in pivotal studies”, a mid-level valuation point: neither a fire sale at a low pre-IND valuation, nor a hard sell at a high post-NDA valuation.

Six months later Corxel secured a US$287 million D1, effectively backstopping VCT220’s global development funding in one go. From Vincentage’s perspective, this amounts to outsourcing the task of “how to raise the next US$500 million for a US Phase 3” to a vehicle with a higher valuation and a smoother investor story. Vincentage’s own cash flow can be carried forward by milestone cash subsequently triggered by Corxel + its share of Chinese market sales + a potential deal with a second regional partner.

Three clear valuation inflection points are already structured:

• China NDA acceptance (expected H2 2026) → approval (expected H2 2027 to 2028): triggers regulatory milestone cash flow under the Corxel agreement, and opens the window for Vincentage’s commercialization revenue in the Chinese market.
• Corxel’s US obesity Phase 2 topline (company says “later this year”, i.e. H2 2026): if the data maintain the efficacy and safety profile of the China Phase 2/3, it would directly raise the valuation of the ex-China asset and provide the basis for Corxel’s US Phase 3 design and FDA pathway negotiations. This is also the single most important value catalyst in the next 12 months.
• A potential second ex-China regional partner deal (e.g. single regions such as Japan, the EU or Southeast Asia): Corxel holds the ex-Greater China rights as a whole, but Corxel itself can do regional sublicenses, contributing an additional tier of cash flow to VCT220’s global valuation. This depends on Corxel’s capital and commercial strategy, and the timing cannot be forced.

Matching this to financing milestones: completing BD on this asset before the main readout was correct; now all the important cash flow catalysts are concentrated in the two years from H2 2026 to 2028. In these two years Vincentage does not need to go back to the market with a story of “how we will grow big on our own”; it just needs to push the China NDA through smoothly + have the second/third indication (hypertension, T2D) data read out on time.

Being able to supply drug continuously for 52 weeks to an 840-patient Phase 3, while supporting Corxel’s US Phase 2 enrollment, plus a parallel China hypertension Phase 2, means CMC process maturity and the GMP system have in effect already been “proven by running”. This is a hard constraint that doesn’t need much worry at the Phase 3 stage.

Vincentage is small, unlikely to build its own plant, and has not publicly disclosed specific CDMO partners; it should mainly rely on outsourced manufacturing. Synthesis, solid dosage, stability and release testing for small-molecule GLP-1s are relatively standardized processes; scaling from China to US GMP standards is far easier than for peptides or biologics. Once the “no refrigeration or light protection” product USP is delivered, it brings a corresponding exemption from packaging and cold-chain investment — hard currency for reaching lower-tier channels.

What really needs attention is whether stability data for commercial batches have been completed, and whether in the future NDA review the NMPA will ask for additional studies on process consistency, impurity profile or critical quality attributes. None of these details have been disclosed publicly and must be observed indirectly through progress in CDE responses after NDA acceptance.

Looking only at Vincentage’s own cumulative public financing of about US$20.3 million, it is a small company by Chinese biotech standards. But VCT220’s real “funding profile” is two stacked tracks: Vincentage covers the China trials + NDA + commercialization preparation; Corxel covers all ex-China development in the US/Europe/T2D. The latter has been backstopped by the US$287 million D1.

Vincentage’s own runway has not been publicly disclosed, but there is an inferable lever: under the Corxel deal, Vincentage should already have received an upfront payment (amount undisclosed), and will keep receiving milestone payments at nodes such as the US Phase 2 topline, Corxel’s decision to start a US Phase 3, and the first ex-China country launch. If upfront + triggered milestones together are enough to cover through China NDA approval in 2027–2028, Vincentage won’t need to raise large equity rounds in that period.

That is the real value of a development path built on out-licensing — not “selling the asset for money”, but “using the asset to swap in execution certainty for the next 24 months”. Vincentage’s core task now is to deliver execution, not to go in and out of capital markets repeatedly.

Two points need vigilance in matching the timeline. First, if Corxel’s US Phase 2 reads out below expectations (on either efficacy or safety), it would feed back into milestone triggers under the Corxel agreement and into due diligence by a potential second ex-China partner; second, if after NDA acceptance the NMPA requires supplementary long-term cardiovascular outcome studies or large-scale RWE, review would be extended by more than a year and the competitive window would narrow accordingly.

The core of the VCT220 story is not the molecule’s own differentiation — over the next 24 months the oral small-molecule GLP-1 lane will first see imported orforglipron approved, followed by 4–5 domestic products launching in a crowd, and the ultimate share gap between VCT220 and Lilly (imported originator) and domestic peers Hengrui, Huadong and Ascletis will most likely depend on “commercial execution” factors such as price, hospital coverage, physician education and commercial insurance expansion, rather than clinical superiority at the molecular level.

What really deserves attention is the company’s choice of strategic structure: no IPO, no in-house commercial build, no large next equity round, but a single, clearly structured ex-China license-out between Phase 2 and 3 that fully decouples “global development” to Corxel, a NewCo jointly backstopped by top VCs, letting itself return to the relatively focused task of “doing the China NDA well, doing China commercialization well, and preparing milestone cash flow and a second regional BD”.

This path has been repeatedly validated in recent years by cases such as Hansoh selling HS-10535 to Merck and Innovent bundling multiple assets to Sanofi. For a Chengdu company that has raised only US$20.3 million in total, pushing a successful Phase 3 oral small-molecule GLP-1 to this position is already textbook asset management.

Three things to watch over the next 12 months: the timing of China NDA acceptance, Corxel’s US Phase 2 topline, and the speed at which IP transparency is completed. If any one goes wrong, the BD valuation will step down a notch. If all three are done, VCT220 has a chance in 2027–2028 to become one of the few benchmark cases among Chinese biotechs that truly close the loop on the path of “first selling ex-China rights as a whole to an overseas NewCo, then realizing value through milestones + China sales”.